Alaunos Therapeutics, Inc. Common Stock (TCRT)

Price$2.87

Value ScoreF

Growth ScoreF

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-35.65%

Price vs S&P 500 (4W)4.22%

VGM Score26.43

Market Capitalization$6.96M

All Metrics

Book Value / Share (Quarterly)$0.54

P/TBV (Annual)0.42x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-88.04%

Cash Flow / Share (Quarterly)$-1.36

Price vs S&P 500 (YTD)-22.70%

Net Profit Margin (TTM)-39320.00%

EPS (TTM)$-2.06

10-Day Avg Trading Volume0.02M

EPS Excl Extra (TTM)$-2.06

EPS (Annual)$-2.14

ROI (Annual)-193.96%

Net Profit Margin (5Y Avg)-170837.58%

Cash / Share (Quarterly)$0.15

Revenue Growth QoQ (YoY)-25.00%

ROA (Last FY)-140.80%

Revenue Growth TTM (YoY)-70.00%

EBITD / Share (TTM)$-2.03

ROE (5Y Avg)-242.29%

Operating Margin (TTM)-39980.00%

Cash Flow / Share (Annual)$-1.26

P/B Ratio5.40x

P/B Ratio (Quarterly)5.28x

Net Income / Employee (Annual)$-4,176,000

EV / Revenue (TTM)1321.22x

Net Interest Coverage (TTM)-17.29x

ROA (TTM)-123.50%

EPS Incl Extra (Annual)$-2.14

Current Ratio (Annual)2.45x

Quick Ratio (Quarterly)0.59x

3-Month Avg Trading Volume0.02M

52-Week Price Return10.47%

Revenue / Employee (TTM)$3,000

Tangible BV / Share (Quarterly)$0.06

P/S Ratio (Annual)1392.02x

Asset Turnover (Annual)0.00x

52-Week High$6.20

Operating Margin (5Y Avg)-167729.21%

EPS Excl Extra (Annual)$-2.14

CapEx CAGR (5Y)-60.17%

Tangible BV CAGR (5Y)-3.96%

26-Week Price Return-19.72%

Quick Ratio (Annual)1.71x

13-Week Price Return-9.24%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.63x

Enterprise Value$6.61M

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-13.48%

Revenue / Employee (Annual)$5,000

Pretax Margin (Annual)-83520.00%

Cash / Share (Annual)$0.59

3-Month Return Std Dev55.90%

Net Income / Employee (TTM)$-4,109,000

ROE (Last FY)-193.96%

Net Interest Coverage (Annual)-9.09x

EPS Basic Excl Extra (Annual)$-2.14

Receivables Turnover (TTM)3.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.06

Receivables Turnover (Annual)1.25x

ROI (TTM)-165.94%

P/S Ratio (TTM)1392.02x

Pretax Margin (5Y Avg)-170837.58%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.16

Price vs S&P 500 (52W)-17.74%

Year-to-Date Return-11.76%

5-Day Price Return17.77%

EPS Normalized (Annual)$-2.14

ROA (5Y Avg)-175.40%

Net Profit Margin (Annual)-83520.00%

Month-to-Date Return11.76%

Cash Flow / Share (TTM)$-0.14

EBITD / Share (Annual)$-2.16

Operating Margin (Annual)-84500.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-228.39%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.06

P/TBV (Quarterly)1.15x

P/B Ratio (Annual)3.35x

Pretax Margin (TTM)-39320.00%

Book Value / Share (Annual)$0.92

Price vs S&P 500 (13W)-18.98%

Beta-1.12x

Revenue / Share (TTM)$0.00

ROE (TTM)-165.94%

52-Week Low$1.67

vGradeF

gGradeF

mGradeC

vgmGradeD

Show chart for

Analyst Recommendations

Dec 2024

Jan 2025

Feb 2025

Mar 2025

2.17

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
TCRTAlaunos Therapeutics, Inc. Common Stock	F	F	C	$2.87
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Alaunos Therapeutics is a preclinical-stage biopharmaceutical company developing small-molecule oral therapies for obesity and metabolic disorders. Its lead program, ALN1001, aims to differentiate itself from GLP-1 receptor agonists by preserving lean muscle mass while treating obesity. The company is evaluating the compound's effects on lipid metabolism and gene expression to establish a competitive profile in the obesity treatment market.